Name

Insilico Medicine

Legal name

InSilico Medicine

Website

https://insilico.com

Company type

Public

Founded year

2014

Operating status

Ipo

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

AI Drug Discovery Software

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Laboratory Analytical Instruments (3826), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Generative chemistry platform
• Target identification software
• Clinical trial prediction
• Biologics design platform

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Software Licensing (Pharma.AI platform): Subscription and licensing revenue from Pharma.AI platform products (PandaOmics, Chemistry42, Generative Biologics, inClinico) licensed to pharmaceutical and biotech companies; more than 40 pharmaceutical companies use Insilico's technology.
2. Drug Discovery Collaboration Deals (Upfront + Milestones): Large milestone-driven deals with pharma partners combining upfront payments (e.g., $115M from Eli Lilly, $80M from Exelixis), R&D funding, and milestone payments tied to development/regulatory/commercial progress (e.g., Eli Lilly up to $2.75B total, Sanofi up to $1.2B, SK Biopharmaceuticals up to $2.5B+, Servier $888M).
3. Royalties on Net Sales: Tiered royalties on future net sales of products arising from collaborations, including single-digit royalties (e.g., SK Biopharmaceuticals deal) and tiered royalties (Eli Lilly deal).
4. Co-development Revenue (Pipeline Programs): Revenue from co-developed programs with shared global rights (e.g., Hygtia Therapeutics 50/50 co-development of ISM8969), where Insilico is eligible for upfront and milestone payments as the program advances (up to $66M for Hygtia program).
5. Grants and Non-dilutive Funding: Non-dilutive funding including the Bill & Melinda Gates Foundation grant ($700K+) for contraceptive design and other research grants.

Pricing tiers

Go-to-market motion4 records

Core offering

Insilico Medicine develops and commercializes Pharma.AI, an end-to-end generative AI software platform for drug discovery, with modules spanning biology (Biology42: PandaOmics, Generative Biologics, PreciousGPT), chemistry (Chemistry42), and clinical medicine (Medicine42: inClinico, Nach01), plus Science42: DORA LLM research assistant and MMAI Gym. The company also operates an internal pipeline of 30+ AI-discovered and AI-designed drug candidates and licenses/co-develops them with global pharmaceutical partners.

Product overview

Insilico Medicine is a global, clinical-stage, end-to-end generative AI-driven biotech offering a unified platform-plus-modules product architecture. The core platform is Pharma.AI, a commercially available end-to-end generative AI software suite spanning biology, chemistry, and clinical medicine, organized into three families: Biology42 (PandaOmics for AI target and biomarker discovery, with PandaOmics Box as an alternate packaging), Generative Biologics for biologics design, and PreciousGPT under the "Large Language of Life Models (LLLMs)" umbrella; Chemistry42 for generative small-molecule design, retrosynthesis, ADMET prediction, and molecule optimization; and Medicine42, which includes inClinico for AI-driven Phase II clinical trial outcome prediction and Nach01. Layered on top is the MMAI Gym, a service introduced in January 2026 for training and benchmarking large language models on drug discovery tasks, plus the newly announced LabClaw automation system. Complementing the platform, Insilico operates a fully automated robotics laboratory (Life Star, Suzhou) and an Abu Dhabi Generative AI and Quantum Computing R&D Center, and runs a diversified internal drug pipeline of more than 30 AI-discovered/AI-designed preclinical and clinical programs led by INS018_055/Rentosertib (TNIK inhibitor for IPF).

Differentiator

Problem solved

Functional benefit

Brands

• Pharma.AI: End-to-end generative AI software platform for drug discovery, scientific research and sustainability, encompassing Biology42, Chemistry42, and Medicine42.
• PandaOmics
• Chemistry42
• inClinico
• Generative Biologics
• Science42: DORA
• MMAI Gym
• PreciousGPT
• Nach01

Products and services

• Pharma.AI Suite
• PandaOmics Generative AI software for therapeutic target and biomarker discovery with 20+ AI and bioinformatics models, transformer-based NLP knowledge graph of biomedical literature, and ChatPandaGPT natural-language querying. Sold to pharmaceutical and biotech researchers.
• Chemistry42 Generative chemistry platform integrating 40+ generative models (including autoencoders and GANs) with computational and medicinal chemistry methods to generate and optimize drug-like small molecules; supports structure-based and ligand-based design with AlphaFold integration. Sold to pharmaceutical and biotech researchers.
• Generative Biologics Generative AI platform module for designing therapeutic biologics including therapeutic proteins and antibody candidates, sold as part of the Pharma.AI suite.
• inClinico Generative AI platform that uses a multimodal forecast (small-molecule chemical properties, transcriptomics, text, and clinical trial protocols) to predict Phase II to Phase III clinical trial transition probability. Sold to pharmaceutical and biotech customers.
• Science42: DORA Draft Outline Research Assistant workflow built on Insilico's Science42 large language model platform, supporting AI-assisted scientific literature drafting, target discovery research, and pharmaceutical R&D workflows.
• Nach01 Generative AI application under the Medicine42 suite of Pharma.AI, listed in the platform navigation.
• PreciousGPT Large Language of Life Models (LLLMs) generative AI offering under the Pharma.AI umbrella, presented alongside other LLM-based tools.
• MMAI Gym Multi-Modal AI Gym — a service/training platform for LLM developers that offers 3-month training subscriptions to improve model drug discovery fitness and access to CSI/BSI Pharmaceutical Super Intelligence models.
• LabClaw Intelligent automation system intended to advance drug discovery from automation to autonomy, integrating with the Suzhou Life Star robotics laboratory and the broader MMAI Gym ecosystem.
• INS018_055 / Rentosertib (ISM001-055) Lead clinical-stage small-molecule TNIK inhibitor designed by Insilico's generative AI for an AI-discovered target, for idiopathic pulmonary fibrosis (IPF) and kidney fibrosis; the first AI-discovered and AI-designed drug to enter Phase II trials. Available for licensing/co-development with pharmaceutical partners.

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature9 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput wet-lab biology with machine learning across target identification, hit generation, and translational research — directly comparable end-to-end generative-AI-for-drugs model with partnered pipeline.
• Exscientia: Pioneer in AI-driven small-molecule design with a partnered pipeline (e.g., DSP-1181 with Sumitomo, BMS collaborations) using generative chemistry and active learning — directly comparable generative chemistry platform and pharma partnership GTM.
• Schrödinger: Physics-based computational chemistry and AI-driven molecular simulation platform with both a software business (licensed to pharma/biotech) and an internal drug pipeline — closely comparable hybrid software-plus-pipeline business model.
• Isomorphic Labs: Alphabet-backed AI drug discovery company building on DeepMind's AlphaFold with partnered programs including a $3B+ collaboration with Novartis and a $1.7B Eli Lilly deal — directly comparable in scaling AI platform deals with Big Pharma.
• XtalPi: AI-plus-robotics drug discovery company combining quantum physics, ML, and automated labs with a large pharma partnership base (e.g., Pfizer) — directly comparable as a Greater-China-based, end-to-end AI drug discovery platform with similar GTM.
• BenevolentAI: AI-driven drug discovery company with target identification and clinical pipeline assets (e.g., baricitinib repurposing), using biomedical knowledge graphs and ML — directly comparable target-discovery-plus-platform GTM.

Emerging players

• AbCellera Biologics: AI-enabled antibody discovery platform with pharma partnerships (e.g., Eli Lilly for COVID antibodies) and an internal biologics pipeline — comparable as a tech-forward biologics discovery company with similar pharma licensing GTM.
• Relay Therapeutics: Precision medicine company using computational/motion-based drug design to develop targeted oncology therapies (e.g., RLY-4008) — comparable motion-based generative design approach applied to a focused clinical pipeline.
• Generate:Biomedicines: Generative biology company (Flagship-founded) using ML to design de novo protein therapeutics including antibodies and peptides — directly comparable Generative Biologics-like capabilities to Insilico's biologics module.
• Atomwise: AI small-molecule discovery company using convolutional neural networks for structure-based design with multi-target pharma partnerships (e.g., Sanofi, Bayer) — comparable AI drug discovery GTM via partnership deals with major pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InsilicoMeds
• Facebookfacebook.com/insilicomedicine
• LinkedInlinkedin.com/company/in-silico-medicine-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors40 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insilico Medicine